Edoxaban Review ‘Not About Comparative Efficacy,’ FDA Says
Executive Summary
Structured benefit/risk framework requires consideration of current treatment options, agency says in asking its cardio-renal advisory committee to consider the existence of three other novel anticoagulants when weighing the poor efficacy seen with Daiichi’s Factor Xa inhibitor in a large patient subgroup.
You may also be interested in...
Savaysa Shows The Good And Bad Of Being Late In Class
As Daiichi’s experience suggests, sponsors of later-in-class products may face unfavorable efficacy comparisons to their earlier-approved brethren and challenges in qualifying for a priority review; however, risk management obligations may be less burdensome than for first-in-class products.
Abuse-Deterrent Opioids Could Gain Significant First-Mover Advantage Under FDA Guidance
FDA recommends head-to-head studies against already marketed products – an unusual development policy for the agency.
FDA Approves Daiichi’s Savaysa, But Not For AF Patients With Normal Kidney Function
The Japanese pharma scored an approval of its oral anticoagulant, but is at a disadvantage to competition due to a label that restricts use to patients with renal impairment.